October 11, 2017
11 am to 12 pm EDT
Charles Mathews, Vice President will:
- Provide an overview of developments in immuno-oncology diagnostics
- Discuss possible challenges/issues with incorporation of a variety of test methods into routine clinical care
- Highlight different test access, quality demonstration, and evidence development pathways
- Recognize key reimbursement approaches/considerations for both companion and non-companion tests
- Review several possible testing pattern scenarios and implications for innovators
Register for the free webinar here.
Next Level Pharma MedTech Commercial Leaders Forum USA
Crowne Plaza Hotel
Princeton, New Jersey
On site at the Next Generation Dx Summit, Vice President, Charles Mathews tells Diagnostics World editor Allison Proffitt that the diagnostics industry needs to create its own evidence standard and to outline clearly what levels of evidence should be required.
August 21, 2017
GenomeWeb: ‘Insurers Turn to Automated Prior Authorization Programs to Rein in Genetic Testing Use’
May 31, 2017
Boston Healthcare Associates and Data Information Intelligence Announce Global Life Sciences Data Commercialization Partnership Click here to read more.
April 5, 2017
Research by Boston Healthcare highlights new data demonstrating increased value from innovative biopharmaceutical treatments for Rheumatoid Arthritis. Click here to read more.
June 23, 2015
Boston Healthcare releases latest white paper in the PhRMA-sponsored series focused on recognizing value in biopharmaceutical innovation, The Value of Innovation in Oncology: Recognizing Emerging Benefits Over Time. Click here to read the press release.
March 4, 2015
Boston Healthcare instrumental in developing tools to estimate the cost and value of next-generation sequencing (NGS) for the Association for Molecular Pathology (AMP). AMP recently released these health economic evaluation tools for genome sequencing procedure CPT codes including a micro-costing analysis template tool that molecular diagnostic laboratories can use to calculate the cost of their next-generation sequencing assays used to perform these procedures. Also three health economic models, including customized models for whole exome analysis, tumor panel for non-small cell lung cancer (NSCLC), and hearing loss are now available to help demonstrate the economic value of NGS procedures. Click here to read the AMP press release. Click here for access to the AMP models and to view a webinar describing the projects.
September 10, 2014
Boston Healthcare releases new white paper, The Value of Innovation in HIV/AIDS Therapy, as part of PhRMA-sponsored series focused on recognizing value in biopharmaceutical innovation.
November 18, 2014
As featured in Medical Design Technology magazine, Boston Healthcare participates in first annual Parker Human Motion Summit which focused on industry perspectives for demonstrating the value of innovative neurorehabilitation technologies. Leading practitioners, executives, and payment policy makers gathered for insightful panel discussions and debates on topics ranging from clinician experiences utilizing new devices and techniques in rehabilitation programs, to hospital administrator insights into purchasing and decision making processes for early adoption, and to payment policy makers perspectives on reimbursement for emerging neurorehabilitation products in the clinic and the home. >>
Please click here for more Boston Healthcare news.